Andy K.H. Lim

Dr. Andy K.H. Lim

1. Monash University Department of Medicine, School of Clinical Sciences at Monash Health
+1
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in International Journal of Nephrology and Renovascular Disease
Verified
Journal Article
Open access
Andy K.H. LimAndy K.H. Lim
Andy K.H. Lim
Diabetic nephropathy is a significant cause of chronic kidney disease and end-stage renal failure globally. Much research has been conducted in both basic science and clinical therapeutics, which has enhanced understanding of the pathophysiology of diabetic nephropathy and expanded the potential therapies available. This review will examine the current concepts of diabetic nephropathy management in the context of some of the basic science and pathophysiology aspects relevant to the approaches taken in novel, investigative treatment strategies.

21 August 2012 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
Andy K.H. LimAndy K.H. Lim
Andy K.H. Lim
GTGregory H. Tesch
Gregory H. Tesch
Diabetic nephropathy is the leading cause of end-stage kidney disease worldwide but current treatments remain suboptimal. This review examines the evidence for inflammation in the development and progression of diabetic nephropathy in both experimental and human diabetes, and provides an update on recent novel experimental approaches targeting inflammation and the lessons we have learned from these approaches. We highlight the important role of inflammatory cells in the kidney, particularly infiltrating macrophages, T-lymphocytes and the subpopulation of regulatory T cells. The possible link between immune deposition and diabetic nephropathy is explored, along with the recently described immune complexes of anti-oxidized low-density lipoproteins. We also briefly discuss some of the major inflammatory cytokines involved in the pathogenesis of diabetic nephropathy, including the role of adipokines. Lastly, we present the latest data on the pathogenic role of the stress-activated protein kinases in diabetic nephropathy, from studies on the p38 mitogen activated protein kinase and the c-Jun amino terminal kinase cell signalling pathways. The genetic and pharmacological approaches which reduce inflammation in diabetic nephropathy have not only enhanced our understanding of the pathophysiology of the disease but shown promise as potential therapeutic strategies.

1 February 2011 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
GTG. H. Tesch
G. H. Tesch
Andy K.H. LimAndy K.H. Lim
Andy K.H. Lim
The db/db mouse is the most widely used animal model of type 2 diabetic nephropathy. Recent studies have utilized genetic backcrossing with transgenic mouse strains to create novel db/db strains that either lack or overexpress specific genes. These novel strains [ICAM-1−/−, CCL2−/−, MKK3−/−, osteopontin−/−, plasminogen activator inhibitor-1 (PAI-1)−/−, endothelial nitric oxide synthase−/−, SOD-Tg, rCAT-Tg] have provided valuable insights into the molecular mechanisms which promote diabetic renal injury. In addition, surgical removal of one kidney has been shown to accelerate injury in the remaining kidney of diabetic db/db mice. A number of novel therapeutic agents have also been tested in db/db mice, including inhibitors of inflammation (chemokine receptor antagonists, anti-CCL2 RNA aptamer, anti- c-fms antibody); oxidative stress (oxykine, biliverdin); the renin-angiotensin-aldosterone system (aliskiren, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, eplerenone); advanced glycation end products (AGE; pyridoxamine, alagebrium, soluble AGE receptor); angiogenesis (NM-3, anti-CXCL12 RNA aptamer, soluble Flt-1); lipid accumulation (statins, farnesoid X receptor agonists, Omacor); intracellular signaling pathways (PKC-β or JNK inhibitors); and fibrosis [transforming growth factor (TGF)-β antibody, TGF-βR kinase inhibitor, soluble betaglycan, SMP-534, CTGF-antisense oligonucleotide, mutant PAI-1, pirfenidone], which have identified potential therapeutic targets for clinical translation. This review summarizes the advances in knowledge gained from studies in genetically modified db/db mice and treatment of db/db mice with novel therapeutic agents.

14 March 2020 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Andy K.H. LimAndy K.H. Lim
Andy K.H. Lim
Rhabdomyolysis is a syndrome of skeletal muscle injury with release of cellular constituents such as potassium, phosphate, urate and intracellular proteins such as myoglobin into the circulation, which may cause complications including acute kidney injury, electrolyte disturbance and cardiac instability. Abnormal liver function tests are frequently observed in cases of severe rhabdomyolysis. Typically, there is an increase in serum aminotransferases, namely aspartate aminotransferase and alanine aminotransferase. This raises the question of liver injury and often triggers a pathway of investigation which may lead to a liver biopsy. However, muscle can also be a source of the increased aminotransferase activity. This review discusses the dilemma of finding abnormal liver function tests in the setting of muscle injury and the potential implications of such an association. It delves into some of the clinical and experimental evidence for correlating muscle injury to raised aminotransferases, and discusses pathophysiological mechanisms such as oxidative stress which may cause actual liver injury. Serum aminotransferases lack tissue specificity to allow clinicians to distinguish primary liver injury from muscle injury. This review also explores potential approaches to improve the accuracy of our diagnostic tools, so that excessive or unnecessary liver investigations can be avoided.

9 December 2008 in Diabetologia
Verified
Journal Article
Closed access
PDF file
Andy K.H. LimAndy K.H. Lim
Andy K.H. Lim
DND. J. Nikolic-Paterson
D. J. Nikolic-Paterson
FMF. Y. Ma
F. Y. Ma
EOE. Ozols
E. Ozols
MTMerlin Thomas
Merlin Thomas
GTG. H. Tesch
G. H. Tesch

23 May 2009 in Diabetologia
Verified
Journal Article
Closed access
PDF file
Andy K.H. LimAndy K.H. Lim
Andy K.H. Lim
FMF. Y. Ma
F. Y. Ma
DND. J. Nikolic-Paterson
D. J. Nikolic-Paterson
MTMerlin Thomas
Merlin Thomas
LHL. A. Hurst
L. A. Hurst
GTG. H. Tesch
G. H. Tesch